AOTI (AOTI) H2 2024 earnings summary

Executive summary

• Achieved strong revenue growth of 32.9% year-over-year to $58.4 million, driven by Medicaid and VA expansion, commercial execution, and increased market access for TWO2 therapy.

• Diversified revenue mix away from the VA, with Medicaid and commercial sectors gaining share; VA now under 60% of revenues, down from 70% last year.

• Expanded into nine Medicaid states, secured a five-year VA contract extension, and launched the NEXA product line with FDA clearance for home care and a major US distribution agreement.

• Strengthened management with new CFO, expanded sales and market access teams, and advanced the Eyes on the Wound value-based care platform.

Financial highlights

• Revenue rose to $58.4 million from $43.9 million year-over-year; Medicaid revenue up 84% to $21.5 million, VA up 9% to $34.4 million, and other segments tripled to $2.5 million.

• Gross margin improved to 88% from 85.6%, reflecting a favorable shift in business mix.

• Adjusted EBITDA increased 368.7% to $8.1 million, with margin rising from 3.9% to 13.8%.

• Loss before tax narrowed from $7.7 million to $0.9 million; underlying profit (excluding one-offs) improved from a $1.6 million loss to a $4.3 million profit.

• Cash and cash equivalents rose to over $9 million, reflecting IPO proceeds and improved net cash position.

Outlook and guidance

• Forecasting 27–30% revenue growth for 2025, with Adjusted EBITDA margin expected between 14–16%, weighted to the second half as new business areas gain traction.

• Plans to open two to three new Medicaid states annually and deepen penetration in existing and new commercial sectors.

• Anticipates continued international expansion, especially in the UK, Germany, and the Middle East.

• Awaiting CMS Medicare coverage determination, which is expected to be a significant growth accelerant when granted.

• Continued investment in sales, market access, and value-based care models to drive profitable growth.